http://purl.org/np/RAkipqPTQ7TjgGtL0I8uP0rWaFcX-rMElSMMUeWjDXa6g#Head http://purl.org/np/RAkipqPTQ7TjgGtL0I8uP0rWaFcX-rMElSMMUeWjDXa6g http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAkipqPTQ7TjgGtL0I8uP0rWaFcX-rMElSMMUeWjDXa6g#assertion http://purl.org/np/RAkipqPTQ7TjgGtL0I8uP0rWaFcX-rMElSMMUeWjDXa6g http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAkipqPTQ7TjgGtL0I8uP0rWaFcX-rMElSMMUeWjDXa6g#provenance http://purl.org/np/RAkipqPTQ7TjgGtL0I8uP0rWaFcX-rMElSMMUeWjDXa6g http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAkipqPTQ7TjgGtL0I8uP0rWaFcX-rMElSMMUeWjDXa6g#pubinfo http://purl.org/np/RAkipqPTQ7TjgGtL0I8uP0rWaFcX-rMElSMMUeWjDXa6g http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAkipqPTQ7TjgGtL0I8uP0rWaFcX-rMElSMMUeWjDXa6g#assertion http://purl.obolibrary.org/obo/DOID_9538 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAkipqPTQ7TjgGtL0I8uP0rWaFcX-rMElSMMUeWjDXa6g#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_9538 http://purl.org/np/RAkipqPTQ7TjgGtL0I8uP0rWaFcX-rMElSMMUeWjDXa6g#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAkipqPTQ7TjgGtL0I8uP0rWaFcX-rMElSMMUeWjDXa6g#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB01041 http://purl.org/np/RAkipqPTQ7TjgGtL0I8uP0rWaFcX-rMElSMMUeWjDXa6g#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAkipqPTQ7TjgGtL0I8uP0rWaFcX-rMElSMMUeWjDXa6g#association http://www.w3.org/2000/01/rdf-schema#label thalomid in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma mm 1 1 thalomid is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum enl 1 2 thalomid in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma mm see clinical studies 14 1 thalomid is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum enl thalomid is not indicated as monotherapy for such enl treatment in the presence of moderate to severe neuritis thalomid is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of enl recurrence see clinical studies 14 2 http://purl.org/np/RAkipqPTQ7TjgGtL0I8uP0rWaFcX-rMElSMMUeWjDXa6g#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAkipqPTQ7TjgGtL0I8uP0rWaFcX-rMElSMMUeWjDXa6g#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAkipqPTQ7TjgGtL0I8uP0rWaFcX-rMElSMMUeWjDXa6g#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB01041 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAkipqPTQ7TjgGtL0I8uP0rWaFcX-rMElSMMUeWjDXa6g#provenance http://purl.org/np/RAkipqPTQ7TjgGtL0I8uP0rWaFcX-rMElSMMUeWjDXa6g#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAkipqPTQ7TjgGtL0I8uP0rWaFcX-rMElSMMUeWjDXa6g#pubinfo http://purl.org/np/RAkipqPTQ7TjgGtL0I8uP0rWaFcX-rMElSMMUeWjDXa6g#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAkipqPTQ7TjgGtL0I8uP0rWaFcX-rMElSMMUeWjDXa6g#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAkipqPTQ7TjgGtL0I8uP0rWaFcX-rMElSMMUeWjDXa6g#sig http://purl.org/nanopub/x/hasSignature ZXlOjoIzDLCrD/wPGV2Lh7qzKEoRLXEbQrwurEoEBhECBhJMkAm2vrN49qOmZjdtHVS2mSQfCDSneszlcEet2Uldp4E4gysU6jQ4ELJsSITMun7VUqvLWk9g2oMGdTLGkWjTbzfnVdKepN/TlPYx5xm0HYZ5CS6p8jhA10PA1UY= http://purl.org/np/RAkipqPTQ7TjgGtL0I8uP0rWaFcX-rMElSMMUeWjDXa6g#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAkipqPTQ7TjgGtL0I8uP0rWaFcX-rMElSMMUeWjDXa6g http://purl.org/np/RAkipqPTQ7TjgGtL0I8uP0rWaFcX-rMElSMMUeWjDXa6g http://purl.org/dc/terms/created 2021-06-12T16:29:21.636+02:00 http://purl.org/np/RAkipqPTQ7TjgGtL0I8uP0rWaFcX-rMElSMMUeWjDXa6g http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAkipqPTQ7TjgGtL0I8uP0rWaFcX-rMElSMMUeWjDXa6g https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAkipqPTQ7TjgGtL0I8uP0rWaFcX-rMElSMMUeWjDXa6g https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAkipqPTQ7TjgGtL0I8uP0rWaFcX-rMElSMMUeWjDXa6g https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs